Psyched Wellness Ltd. announced it has initiated first steps towards a clinical sleep study for a structure/function claim for the Company's proprietary extract from Amanita Muscaria mushrooms, AME-1. The study will be led by Psyched Wellness's Board member and Head of the Company's Scientific Committee, Professor David Nutt, a psychiatrist and the Edmond J. Safra Professor of psychopharmacology at the Imperial College London and the Chair of the Scientific Advisory Board for COMPASS Pathways. The aim of the study is to carry out an assessment of a novel sleep enhancing food supplement for self- declared insomniacs based on both subjective and objective sleep measures, including residual effects. Several conventional and over-the-counter sleep medications have residual effects and drowsiness. Psyched Wellness aims to develop new treatments that show a lack of residual hangover effects and increased alertness during the day.